Treating locally advanced or metastatic prostate cancer patients - who experience disease progression after first-line, castration-based therapy - with ‘step-up’ to Combined Androgen Blockade (CAB) therapy can substantially prolong the ‘hormonal response'1. This is the key finding of new research presented recently at the European Association of Urology (EAU) meeting in Berlin, Germany.
